Delving into the Latest Updates on Demplatin Pegraglumer with Synapse

Overview

Basic Info

Drug Type

Polymer

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Advanced Malignant Solid NeoplasmHead and Neck Neoplasms

Originator Organization

NANO MRNA Co., Ltd.

Active Organization-

Inactive Organization

NANO MRNA Co., Ltd.

License Organization

NANO MRNA Co., Ltd.

Orient Europharma Co. Ltd.

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

In Phase IIa, dose-escalation study to determine the optimum tolerated dose and a recommended Phase IIb (RPIIb) dose in combination with pembrolizumab in subjects with recurrent or metastatic squamous cell carcinoma of the head and neck who have failed platinum or a platinum containing regimen.
In Phase IIb, randomized control study between NC-6004 in combination with pembrolizumab versus pembrolizumab alone in the same subject population as Part 1 at the RPIIb dose identified in PIIa.

Start Date01 Jul 2019

Sponsor / Collaborator

NANO MRNA Co., Ltd.

[+1]

EUCTR2016-000866-44-BG

/ Not yet recruitingPhase 1/2

Phase I/II Clinical Trial of NC-6004 in Combination with 5-FU and Cetuximab as First-line Treatment in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of The Head and Neck

Start Date21 Mar 2017

Sponsor / Collaborator

NANO MRNA Co., Ltd.

100 Clinical Results associated with Demplatin Pegraglumer

Login to view more data

100 Translational Medicine associated with Demplatin Pegraglumer

Login to view more data

100 Patents (Medical) associated with Demplatin Pegraglumer

Login to view more data

18

Literatures (Medical) associated with Demplatin Pegraglumer

01 Feb 2021·Journal of Nanoscience and Nanotechnology

Effect of Nano-Platinum on Proliferation and Apoptosis of Non-Small Cell Lung Cancer Cells via P53 Pathway

Article

Author: Zhao, Long ; Hu, Fangjuan ; Liu, Yiqun

This paper studies the non-small cell lung cancer with interventional treatment of polyethylene imine-coated platinum nanoclusters. The relationship between the inhibition of non-small cell lung cancer cell proliferation, apoptosis, and the expression of its related apoptotic protein p53. Apoptosis experiments were applied was used to detect the effect of nanoplatin on A549 cells. Western blot was used to detect the expression of p53 protein in A549 cells after nanoplatin treatment. We co-cultured nanoplatin with cells for 4 hours and performed nuclear staining. Observed by laser confocal microscopy, we found that nanoplatin can enter the nucleus and cytoplasm of non-small cell lung cancer A549 cells, and the phenomenon of drug entering the nucleus is very obvious. Treatment of non-small cell lung cancer with A549 cells at different concentrations of nanoplatin for 24 hours, with the increase of the concentration, the proliferation inhibition rate of non-small cell lung cancer gradually increased. Treatment of cisplatin-resistant non-small cell lung cancer cells with different concentrations of nanoplatin for 24 hours, as the concentration increases, the proliferation inhibition rate of non-small cell lung cancer gradually increases. After treatment of A549 cells with different concentrations of nanoplatin for 24 hours, the apoptosis rate of A549 cells gradually increased with the increase of drug concentration. Finally, we conclude that nanoplatin has not only inhibitory and pro-apoptotic effects on non-small cell lung cancer cells, but also fluorescent labeling. Compared with cisplatin, nanoplatin can significantly inhibit the proliferation of non-small cell lung cancer cells and overcome its cisplatin resistance. The p53-related signaling pathway may participate in the process of apoptosis and reverse the process of cisplatin resistance, but the specific mechanism and whether there are other signaling pathways involved Further research is needed.

18 Aug 2020·Oncotarget

A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer

Article

Author: Volovat, Constantin ; Bobe, Iulian ; Ciuleanu, Tudor-Eliade ; Koynov, Krassimir ; Koralewski, Piotr ; Volovat, Simona Ruxandra ; Croitoru, Adina ; Cerea, Giulio ; Stabile, Stefano ; Osada, Atsushi ; Olson, Juneko E. Grilley

NC-6004 is a nanoparticle developed using micellar technology that can improve release of cisplatin, a standard treatment for many cancer types, and achieve selective distribution to tumors. Here, in the Phase II portion of this study, the activity, safety, tolerability, and effects on quality of life of NC-6004 in combination with gemcitabine was examined in 34 squamous non-small cell lung carcinoma (NSCLC) patients, 50 biliary tract cancer patients, and 13 bladder cancer patients. All patients received 135 mg/m² NC-6004 on day one and 1,250 mg/m² gemcitabine on days one and eight. The median progression-free survival was 3.9 months in NSCLC patients, 4.3 months in biliary tract cancer patients, and 6.8 months in bladder cancer patients fit for cisplatin treatment. The most frequently reported Grade 3 Treatment Emergent Adverse Events across all cohorts were nausea, anemia and neutropenia, and hyponatremia. Quality of life measures for patients who received the combined therapy were generally consistent with expectations for patients undergoing chemotherapy. Overall, combined NC-6004 and gemcitabine treatment resulted in long-lasting antitumor activity and had a favorable safety profile, suggesting that it should be investigated further as a therapy for various types of cancer.

09 Dec 2019·BiomacromoleculesQ2 · CHEMISTRY

Cancer Nanomedicines Based on Synthetic Polypeptides

Q2 · CHEMISTRY

Review

Author: Xu, Hao ; Sun, Huanli ; Zhong, Zhiyuan ; Gu, Xiaolei ; Deng, Chao ; Zhang, Qiang

Nanomedicines are deemed as the most promising treatment modality for malignant cancers. Particularly, cancer nanomedicines based on synthetic polypeptides have gained interest because they possess excellent safety, unique hierarchical structure, and tailorable functionalities to suit for delivery of diverse drugs including synthetic drugs, peptides, proteins, and nucleic acids. A few polypeptide-based nanoformulations (e.g., NK105, NC6004, NK911, CT2103) are under phases I-III clinical investigation for treating patients with advanced solid tumors. In recent years, progress has been made in the development of robust and high drug loading, tumor-targeting, membrane-disrupting, and stimuli-sensitive nanomedicines from de novo functional polypeptides, which afford not only better safety and reduced adverse effects, but also further improved anticancer efficacy over clinical formulations. Moreover, virus-mimicking vehicles have been devised from polypeptides for efficient nonviral delivery of highly potent peptides, proteins, and nucleic acids, greatly advancing biotherapy for cancers. In this Perspective, we highlight the state-of-the-art design and fabrication of cancer nanomedicines based on synthetic polypeptides and, at the end, give our viewpoints on their future development for targeted cancer therapy and potential challenges for clinical translation.

100 Deals associated with Demplatin Pegraglumer

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14807

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and Neck Neoplasms	Phase 2	Japan	NANO MRNA Co., Ltd.	11 Dec 2021
Advanced Malignant Solid Neoplasm	Phase 2	Bulgaria	NANO MRNA Co., Ltd.	01 May 2014
Advanced Malignant Solid Neoplasm	Phase 2	Italy	NANO MRNA Co., Ltd.	01 May 2014
Advanced Malignant Solid Neoplasm	Phase 2	Poland	NANO MRNA Co., Ltd.	01 May 2014
Advanced Malignant Solid Neoplasm	Phase 2	Romania	NANO MRNA Co., Ltd.	01 May 2014
Advanced Malignant Solid Neoplasm	Phase 2	United States	NANO MRNA Co., Ltd.	01 May 2014